`Int’?] Application No: PCT/EP2020/075541
`Docket No. KATO060PA/P186468USPC
`Date: March 14, 2022
`Preliminary Amendment at National-Stage Entry
`
`AMENDMENTS TO THE SPECIFICATION
`
`Please insert thefollowing heading and paragraph immediately after the title on page I of the
`original application:
`
`CROSS REFERENCES TO RELATED APPLICATIONS
`
`This application is a national-stage application under 35 U.S.C. § 371 of International Application
`
`No. PCT/EP2020/075541, filed September 11, 2020, which International Application claims
`
`benefit of priority to European Patent Application No. 19197202.5, filed September 13, 2019.
`
`Please replace all text beginning at page 5, line 29, through page6, line 21, of the original
`application with the following:
`
`
`
`DETAILEDDESCRIPTHON
`
`Fieuretegends
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`Figuret FIGS. 1A—1B: Schematic representation of 1) PELAV-YFV17D-LASV-GPC(FIG. 1A)
`
`and 2) PLLAV-YFV17D-LASV-GPCcs (FIG. 1B).
`
`Figure FIGS. 2A-2B: FIG.2A) Plaque phenotype of YFV17D-LASV-GPC compared to
`
`YFV17D. FIG.2B) Virus stability: RT-PCR analysis of the virus samples harvested during serial
`
`passaging (in BHK-21J and VeroE6) of the YFV17D-LASV-GPC virus. C+, control positive
`
`PLLAV-YFV17D-LASV-GPC; -RT: RT-PCR reaction without reverse transcriptase; RNA: RT-
`
`PCRreaction with the virus RNA.
`
`Figure-3 FIG. 3: Schematic vaccination schedule. AG129 mice were vaccinated with PLLAV-
`
`YFV17D-LASV-GPC(25 ug,i.p.) or YFV17D-LASV-GPC (375 PFU).
`
`Page 2 of 12
`
`
`
`Serial No. <Unassigned>
`Int’?] Application No: PCT/EP2020/075541
`Docket No. KATO060PA/P186468USPC
`Date: March 14, 2022
`Preliminary Amendment at National-Stage Entry
`
`Figure4 FIGS. 4A-4B: Analysis of cellular immunity in vaccinated AG129 mice. FIG. 4A)
`
`Representative IFN-y ELISPOT wells after 48 hours of stimulation of splenocytes with the
`
`indicated antigen. FIG. 4B) Spots per six hundred thousand splenocytes in IFN-y ELISPOTafter
`
`48 hours of stimulation with the indicated antigen. For each mouse, samples were analyzed in
`
`duplicates and values are normalized by subtracting the number of spots in control wells
`
`(ovalbumin stimulated).
`
`Figure-5 FIGS. SA-5B: FIG.5A) Plaque phenotype of YFV17D-LASV-GPCcs compared to
`
`
`
`YFV17D. FIG.5B) Co-expression of LASV-GPC and YFV_antigens detected by
`
`
`
`immunofluorescence of BHK21J cells infected with supernatantof cells transfected with PLLAV-
`
`YFV17D-LASV-GPCcs .Cells were fixed 48h post-infection and stained for LAV-GPC(red) and
`
`YFV (green).
`
`Figure-6 FIGS. 6A—6B: FIG.6A) Schematic vaccination schedule. AG129 mice were vaccinated
`
`subcutaneous (SC) with YFV17D-LASV-GPCcs (250 PFU). FIG.6B) Analysis of cellular
`
`immunity in vaccinated AG129 mice. Representative IFN-gamma ELISPOT wells after 48 hours
`
`splenocyte stimulation with the indicated antigen. Spots per six hundred thousand splenocytes in
`
`IFN-gamma ELISPOTafter 48 hours of stimulation with the indicated antigen. For each mouse,
`
`samples were analyzed in duplicates and values are normalized by subtracting the numberof spots
`
`in control wells (ovalbumin peptide stimulated).
`
`DETAILED DESCRIPTION
`
`Page 3 of 12
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
